News & Media

Dec 09 / 2021

Hemostemix Announces Soft Lock of Database as Source Document Verification Completed
Oct 28 / 2021

Hemostemix Confirms OTCQB Listing
Oct 19 / 2021

Hemostemix Confirms its OTCQB Application is Filed
Oct 14 / 2021

Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
Oct 04 / 2021

Hemostemix Announces Five Million Unit Private Placement
Oct 04 / 2021

Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain
Sep 21 / 2021

Hemostemix Announces Closing of First Tranche of Unit Private Placement
Sep 14 / 2021

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Sep 08 / 2021

Hemostemix Announces Five Million Unit Private Placement
Jul 06 / 2021

Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Jul 05 / 2021

Hemostemix Announces Warrant Repricing and Extension
Jun 21 / 2021

Peter Lacey Increases his Investment in Hemostemix Inc.
Jun 11 / 2021

Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
May 29 / 2021

Hemostemix Announces the TSX Venture’s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update
May 29 / 2021

Hemostemix Announces that, due to the COVID-19 Pandemic, the Annual and Special Meeting will only be held via Zoom and Shareholders are requested to follow the meeting instructions mailed to the Shareholders of Record
May 25 / 2021

Hemostemix to Present at the Emerging Growth Conference
May 10 / 2021

HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT
May 06 / 2021

Hemostemix Announces Warrant Repricing and Extension
Apr 30 / 2021

Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
Apr 26 / 2021

Hemostemix Reprices and Amends the Terms of its Unit Offering and Debenture Offering
Apr 23 / 2021

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up & HMTXF Up-list
Apr 23 / 2021

(German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
Apr 09 / 2021

Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
Apr 08 / 2021

(German Translation – April 8, 2021)
Apr 08 / 2021

Hemostemix Announces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets Ltd.
Mar 18 / 2021

Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to encrypt its Communications with Regulatory Authorities
Feb 11 / 2021

Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
Jan 28 / 2021

HEMOSTEMIX ANNOUNCES HS 12 – 01 CLINICAL TRIAL COMPLETION OF SUBJECTS’ FOLLOW-UP VISITS AT THE END OF MARCH AND WARRANTS EXTENTED AND REPRICED
Jan 22 / 2021

HEMOSTEMIX ANNOUNCES THE BREAD CONTRACT WITH THE DEPARTMENT OF FOREIGN AFFAIRS, TRADE & DEVELOPMENT CANADA
Jan 04 / 2021

HEMOSTEMIX ANNOUNCES GRANT OF STOCK OPTIONS